Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes Clinical Trial

Official title:

Evaluation of Safety, Tolerance and Pharmacokinetics/Pharmacodynamics of SY-009 Capsules After Single Dose Incremental Oral Administration in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04119947
• Other study ID #: SY009001
• Status: Completed
• Phase: Phase 1
• Start date: March 1, 2019
• Est. completion date: May 30, 2019

Study information

• Verified date: November 2018
• Source: Suzhou Yabao Pharmaceutical R&D Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ⅰ，single-center, randomized, double-blinded, placebo-controlled, single ascending dose trial of SY-009 in healthy subjects.

Description:

This is a randomized, double-blind, placebo-controlled, dosed tolerability, pharmacokinetic / pharmacodynamic study of a single oral SY-009 capsule for Chinese healthy subjects. Plan to screening no more than 64 healthy subjects ， dividing them into 7 dose groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: May 30, 2019
• Est. primary completion date: May 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1?healthy subject:determined by medical history, physical examination, Imaging examination, abdominal B-mode ultrasonography (include liver, gallbladder, pancreas, spleen and kidney), electrocardiogram and laboratory tests. Test results within the normal range for the population or investigator site, or with abnormalities deemed clinically insignificant by the investigator; 2?Gender: Male and female, gender balance; 3?Age: 18-65 years old (including the boundary values); 4?Weight =50kg and 19.0kg/m2=BMI=28.0kg/m2 [BMI=body weight(kg)/height 2 (m2); 5?fasting plasm glucose (FPG): 3.9-6.1mmol/L (excluding the boundary valuses); 6?2h postprandial plasma giucose(2hPPG)<7.8mmol/L; 7?glycosylated hemoglobin (HbA1c) <5.7%;

8?have venous access sufficient to allow blood sampling as per the protocol;

9?Subjects must have informed consent before the study and sign a written informed consent form voluntarily;

10?Subjects can communicate well with investigator and complete the study according to the protocol.

Exclusion Criteria:

1. are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.

2. within 3 months prior to screening, complete or withdraw a clinical study, or are currently conducting a clinical study. Or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

3. have previously completed or withdrawn from this study.

4. have known allergies to compounds related to SY-009 capsules or its adjuvants,or allergic constitution/allergic history, or SGLT1 or SGLT2 inhibitors taken in the past one year.

5. with cardiovascular diseases, respiratory diseases, gastrointestinal diseases, endocrine diseases, blood system diseases, nervous system diseases, disease status can significantly change the absorption, distribution, metabolism and excretion of experimental drugs, or taking experimental drugs will increase the risk of subjects.

6. In the past five years, there has been a history of drug abuse or drug abuse tests positive.

7. show evidence or test positive on any of the following: hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV), Treponema pallidum antibody (S-TP), HIV (HIV1 + 2) antibody.

8. Blood donation or massive blood loss exceeding 400 mL in the first three months prior to screening, or surgical operation and blood or blood component transfusion within the first four weeks prior to screening, or have history of fainting or needle fainting.

9. Subjects who have an average weekly alcohol intake that exceeds and 14 units per week (1 unit = 360 mL beer, 45 mL alcohol content of 40% spirits or 150 mL wine) or subjects unwilling to stop alcohol consumption 24 hours prior to dosing until the completion of each inpatient study period.

10. consume more than 5 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine during the study.

11. intend to use any medicine or health care product within 14 days prior to dosing or during the study.

12. subjects not agree to use reliable contraceptive methods (hormones or barriers or abstinence) during the study period and at least 1 month after administration.

13. women were positive for blood pregnancy test within 24 hours prior to enrollment.

14. pregnant or lactating women.

15. Have special dietary requirements,and impossible to comply with the unified diet.

16. Unable to stop eating chocolate, any caffeine-containing food or beverage (such as pitaya, grapefruit, orange juice, mango, etc.) 48 hours before administration and during the study.

17. Within 30 days prior to screening, any drugs that inhibit or induce drug metabolic enzymes in the liver (e.g. barbiturates, carbamazepine, phenytoin sodium, glucocorticoids, omeprazole, SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines) were used.

18. in the opinion of the investigator , are unsuitable for inclusion in the study,or subjects withdraw informed consent

Related Conditions & MeSH terms

• Diabetes

Intervention

Drug:
• SY-009
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Safety and tolerance of SY-009,Collecting Number of subjects with adverse events as assessed by CTCAE V5.0	Number of subjects with adverse events, major adverse events, serious adverse events, pregnancy events, abnormal Laboratory Values, abnormal vital signs, Abnormal physical examination, Abnormal ECG data.	7 Days
Secondary	area under curve (AUC) of SY-009 following oral administration of single ascending dose	to measure the study drug concentration in blood samples to be collected after drug administration.	3 Days
Secondary	Cmax of SY-009 following oral administration of single ascending dose	to measure the study drug concentration in blood samples to be collected after drug administration.	3 Days
Secondary	T1/2 of SY-009 following oral administration of single ascending dose	to measure the study drug concentration in blood samples to be collected after drug administration.	3 Days
Secondary	CL/F (Clearance rectified) of SY-009 following oral administration of single ascending dose	to measure the study drug concentration in blood samples to be collected after drug administration.	3 Days
Secondary	glucose levels following single dose of SY-009	FPG AUC	3 Days
Secondary	insulin secretion following single dose of SY-009	insulin changes	3 Days
Secondary	C-peptide secretion following single dose of SY-009	C-peptide change	3 Days